SOPHiA GENETICS Temettü

Temettü kriter kontrolleri 0/6

SOPHiA GENETICS şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.0%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$1.01
Gelecekteki Temettü Verimi	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?

Oct 03

SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target

Aug 09

Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)

Aug 08

SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 09

Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector

Feb 12

Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Dec 27

Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge

Nov 09

SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 18

We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth

Mar 10

Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Nov 24

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SOPH şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SOPH şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

SOPHiA GENETICS Piyasaya Karşı Temettü Getirisi

SOPH temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SOPH)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.6%
Sektör Ortalaması (Healthcare Services)	1.0%
Analist tahmini (SOPH) (3 yıla kadar)	0%

Önemli Temettü: SOPH şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SOPH şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SOPH şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SOPH herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

SOPHiA GENETICS Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

SOPHiA GENETICS SA to Report Q3, 2024 Results on Nov 05, 2024

Co-Founder notifies of intention to sell stock

Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?

SOPHiA GENETICS Presents Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

Independent Non-Executive Director notifies of intention to sell stock

SOPHiA GENETICS SA Unveils New Generation of the Sophia Ddmtm Platform At Morgan Stanley Healthcare Conference 2024

Consensus revenue estimates decrease by 13%, EPS upgraded

Independent Non-Executive Director notifies of intention to sell stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target

Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)

Price target decreased by 25% to US$6.00

SOPHiA GENETICS SA Provides Earnings Guidance for the Year 2024

SOPHiA GENETICS SA to Report Q2, 2024 Results on Aug 06, 2024

Co-Founder notifies of intention to sell stock

Insufficient new directors

Sophia Genetics S. A. Launches New Residual Acute Myeloid Application

Executive VP notifies of intention to sell stock

Executive VP & Chief Scientific Officer notifies of intention to sell stock

SOPHiA GENETICS SA, Annual General Meeting, Jun 24, 2024

First quarter 2024 earnings released: US$0.21 loss per share (vs US$0.31 loss in 1Q 2023)

SOPHiA GENETICS Reiterates Earnings Guidance for the Full Year 2024

SOPHiA GENETICS SA to Report Q1, 2024 Results on May 07, 2024

Consensus EPS estimates fall by 11%

SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Price target increased by 8.3% to US$8.67

SOPHiA GENETICS SA Provides Earnings Guidance for 2024

Full year 2023 earnings: EPS misses analyst expectations

SOPHiA GENETICS SA to Report Q4, 2023 Results on Mar 05, 2024

Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector

SOPHiA GENETICS SA Provides Preliminary Earnings Guidance for the Full Year Ending December 31, 2023

Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

SOPHiA GENETICS SA Announces Expanded Suite of Liquid Biopsy Offerings

Price target increased by 9.7% to US$8.50

Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

SOPHiA GENETICS SA Provides Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

SOPHiA GENETICS SA to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?

SOPHiA GENETICS SA to Report Q2, 2023 Results on Aug 08, 2023

SOPHiA GENETICS SA Announces the Nomination of Lila Tretikov to Board of Directors

SOPHiA GENETICS SA, Annual General Meeting, Jun 26, 2023

Price target decreased by 12% to US$7.06

Sophia Genetics SA Reaffirms Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations

Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Price target decreased to US$8.67

High number of new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Sophia Genetics Sa Reaffirms Revenue Guidance for 2022

SOPHiA GENETICS SA to Report Q3, 2022 Results on Nov 08, 2022

SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies

Second quarter 2022 earnings: Revenues miss analyst expectations

SOPHiA GENETICS SA Reiterates Revenue Guidance for 2022

SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M

SOPHiA GENETICS SA to Report Q2, 2022 Results on Aug 09, 2022

We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely

SOPHiA GENETICS SA Appoints Jean-Michel Cosséry to Its Board of Directors

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

SOPHiA GENETICS SA Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS misses analyst expectations

High number of new directors

SOPHiA GENETICS SA, Annual General Meeting, Jun 15, 2022

SOPHiA GENETICS SA to Report Q1, 2022 Results on May 10, 2022

SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth

SOPHiA GENETICS SA Announces Launch of SOPHiA DDM Homologous Recombination Deficiency Solution

SOPHiA GENETICS SA to Report Q4, 2021 Results on Mar 15, 2022

SOPHiA GENETICS SA Reports Strong Traction in the Launch Phase of its DEEP-Lung-IV Multimodal Clinical Study

SOPHiA GENETICS SA Announces Launch of Their DEEP-Lung-IV Clinical Study

Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation

Third quarter 2021 earnings released: US$0.35 loss per share